Clinical trial
Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic…
NCT00159666 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00159666 |
|---|---|
| Title | Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia |
| Official title | A Double-Blind Randomized Placebo-Controlled Trial of the Time to Onset of Pain Relief in Subjects With Post Therapeutic Neuralgia (PHN) Treated With Pregabalin (150 - 600 Mg/Day Flexible Optimized Dose or 300 Mg/Day Fixed Dose) or Placebo |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Post-Herpetic Neuralgia |
| Intervention type | Drug |
| Interventions | pregabalin |
| Enrollment | 255 |
| Start date | Oct 1, 2004 |
| Completion | Jun 1, 2006 |
| First posted | Sep 12, 2005 |
| Last update posted | Jan 22, 2021 |
| Countries | Germany, Italy, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: